Final height after gonadotrophin releasing hormone agonist treatment for central precocious puberty: the Dutch experience.
Final height (FH) data of 96 children (87 girls) treated with GnRH agonist for central precocious puberty were studied. In girls mean FH exceeded initial height prediction by 7.4 (5.7) cm (p < 0.001); FH was significantly lower than target height, but still in the genetic target range. When treatment started < 6 years of age, height gain was significantly higher than when started > 8 years of age. Bone age (BA) and chronological age (CA) at start of treatment, as well as BA advance at cessation of treatment, were the most important variables influencing height gain in multiple regression analysis. BA advance at start of treatment was most important in simple correlation. In girls, GnRHa treatment seems to restore FH into the target range. A younger age and advanced bone age at start of treatment are associated with more height gain from GnRHa treatment.
Mul
D
D
Erasmus University Medical Centre/Sophia Children's Hospital Rotterdam, The Netherlands. mul@alkg.azr.nl
Oostdijk
W
W
Otten
B J
BJ
Rouwé
C
C
Jansen
M
M
Delemarre-van de Waal
H A
HA
Waelkens
J J
JJ
Drop
S L
SL
D001827:Body Height / Q000187:drug effects*; D001846:Bone Development; D001927:Brain Diseases / Q000150:complications*; D002648:Child; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D008297:Male; D011629:Puberty, Precocious / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D012189:Retrospective Studies; D016896:Treatment Outcome
D007987:Gonadotropin-Releasing Hormone